Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S F Dent

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Current Oncology (Toronto, Ont.)|February 17, 2015
Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancerS Chia, S Gandhi, A A Joy, et al.
Lung|October 8, 2005
Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancerS F Dent, A Arnold, D J Stewart, et al.
Breast Cancer Research and Treatment|October 17, 2013
Preference weights for chemotherapy side effects from the perspective of women with breast cancerI Kuchuk, N Bouganim, K Beusterien, et al.
Breast Cancer Research and Treatment|September 17, 2020
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experienceS F Dent, J Botros, M Rushton, et al.
Breast Cancer Research and Treatment|October 14, 2017
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213V Bernstein, S L Ellard, S F Dent, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Current Oncology (Toronto, Ont.)|February 17, 2015
Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancerS Chia, S Gandhi, A A Joy, et al.
Lung|October 8, 2005
Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancerS F Dent, A Arnold, D J Stewart, et al.
Breast Cancer Research and Treatment|October 17, 2013
Preference weights for chemotherapy side effects from the perspective of women with breast cancerI Kuchuk, N Bouganim, K Beusterien, et al.
Breast Cancer Research and Treatment|September 17, 2020
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experienceS F Dent, J Botros, M Rushton, et al.
Breast Cancer Research and Treatment|October 14, 2017
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213V Bernstein, S L Ellard, S F Dent, et al.
Pageof 2